RECN Stock Chart & Stats
$1019.79
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$944.72 - $1,188.76
Previous CloseN/A
VolumeN/A
Average Volume (3M)280.00
Market Cap
$210.77B
Enterprise Value$12.24K
Total Cash (Recent Filing)$380.47M
Total Debt (Recent Filing)$2.37B
Price to Earnings (P/E)22.3
Beta0.10
Next Earnings
Jul 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.30
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume280
Financial Highlights & Ratios
PEG Ratio3.24
Price to Book (P/B)5.20
Price to Sales (P/S)3.81
P/FCF Ratio19.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RECN FAQ
What was Recordati Industria Chimica e Farmaceutica SPA’s price range in the past 12 months?
Recordati Industria Chimica e Farmaceutica SPA lowest stock price was $944.72 and its highest was $1188.76 in the past 12 months.
What is Recordati Industria Chimica e Farmaceutica SPA’s market cap?
Recordati Industria Chimica e Farmaceutica SPA’s market cap is $210.77B.
When is Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date?
Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date is Jul 28, 2026 which is in 2 days.
How were Recordati Industria Chimica e Farmaceutica SPA’s earnings last quarter?
Recordati Industria Chimica e Farmaceutica SPA released its earnings results on May 12, 2026. The company reported $14.595 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Recordati Industria Chimica e Farmaceutica SPA overvalued?
According to Wall Street analysts Recordati Industria Chimica e Farmaceutica SPA’s price is currently Undervalued.
Does Recordati Industria Chimica e Farmaceutica SPA pay dividends?
Recordati Industria Chimica e Farmaceutica SPA does not currently pay dividends.
What is Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate?
Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recordati Industria Chimica e Farmaceutica SPA have?
Currently, no data Available
What happened to Recordati Industria Chimica e Farmaceutica SPA’s price movement after its last earnings report?
Recordati Industria Chimica e Farmaceutica SPA reported an EPS of $14.595 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Recordati Industria Chimica e Farmaceutica SPA?
Currently, no hedge funds are holding shares in MX:RECN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing’s syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.